ICAR's Indigenous ASF Vaccine Offers Lifeline to India's Pig Farmers

African Swine Fever is among the most lethal trans-boundary animal diseases known to veterinary science. Caused by the ASF virus, it triggers high fever, severe haemorrhaging, and mortality that can approach 100 per cent in affected herds. There is no treatment, and until now no commercially approved vaccine existed in India.

The disease arrived on Indian shores in 2020 and quickly spread across multiple states and Union Territories. Its impact has been sharpest in the North-Eastern region, where pig farming is deeply woven into local food systems and household economies. Without a vaccine, authorities have had little option but to rely on rapid diagnosis, mass culling of infected animals, and stringent movement restrictions — measures that contain the disease but do little to protect farmer incomes.

The financial damage from ASF outbreaks in India has been staggering. According to ICAR, the initial outbreaks in Assam in 2020 and 2021 alone resulted in an estimated loss of ₹276 crore from pig mortality and culling. In Mizoram, the disease has proven even more persistent: outbreaks have affected more than 11,382 households through 2025, with cumulative losses estimated at ₹982 crore.

These figures underscore why a preventive solution has been so urgently needed. Smallholder pig farmers — often lacking savings buffers or formal insurance — bear the brunt of every outbreak cycle. Repeated losses erode productive assets, force distress sales, and push vulnerable households further into poverty. ICAR noted that the outbreaks have highlighted the critical need for an indigenous solution capable of building lasting resilience in the sector.

ICAR's MA-104_Cell_Line-Based Live Attenuated ASF Vaccine was developed at the National Institute of High Security Animal Diseases (NIHSAD) in Bhopal. At its core is a novel attenuated ASFV Genotype II virus engineered with unique gene deletions and propagated in the MA-104 cell line — a technically demanding approach that targets the specific strain responsible for outbreaks in India and across Asia.

The vaccine has completed a comprehensive laboratory evaluation covering:

• Sterility and purity testing
• Safety and genetic stability assessments
• Immunogenicity and protective efficacy studies
• Virulence reversion analysis

Critically, it was also field-validated in collaboration with the Department of Animal Husbandry & Dairying (DAHD), confirming that safety and efficacy observed in the laboratory hold under real-world farm conditions. ICAR said the development reflects India's maturing capability to produce world-class animal health solutions domestically.

The significance of this vaccine extends well beyond a single product approval. For years, Indian pig farmers and state animal husbandry departments have operated under a reactive framework — waiting for outbreaks, then attempting containment through culling and quarantine. That approach carries enormous human and economic costs, and it does nothing to protect animals or farmers before an outbreak takes hold.

An effective indigenous vaccine changes the equation entirely, enabling herd-level immunity that can interrupt transmission before losses accumulate. Because the vaccine is domestically developed, it also reduces dependence on foreign supply chains — a strategic advantage for a country where ASF remains an active threat. The next critical milestones will be regulatory approval and commercial-scale manufacturing, which will determine how quickly the vaccine can reach farmers on the ground, particularly in the North-East.